Pfizer Doubles Down on Obesity Fight with Monthly GLP-1 Shot, Aims to Reignite Growth
Positive mid-stage trial results for Pfizer's once-monthly obesity injection, acquired via Metsera, pave the way for a massive late-phase program. The move signals a strategic pivot towards the booming weight-loss drug market as the pharma giant navigates post-pandemic revenue declines.